---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-022879"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2023-05-18T23:59:59+00:00"
generated_at: "2026-06-14T22:01:05.144435+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FibroGen announces positive Phase 3 results for roxadustat in chemotherapy-induced anemia in China

## Summary
- Met primary endpoint: noninferiority to erythropoietin alfa in hemoglobin change from baseline to average weeks 9-13.
- Plan to file supplemental New Drug Application in China with AstraZeneca collaboration.
- 159 non-myeloid malignancy patients enrolled; roxadustat dosed three times weekly for 12 weeks.
- Adverse event profile consistent with prior studies, supporting positive benefit-risk.
- Detailed results to be presented at an upcoming medical conference.

## SEC filing metadata
- accession: 0000950170-23-022879
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2023-05-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017023022879/0000950170-23-022879-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017023022879/fgen-20230518.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-022879
- JSON: https://secwatch.observer/filing/0000950170-23-022879.json
- Plain text: https://secwatch.observer/filing/0000950170-23-022879.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.